Five Things to Know About the Mylan EpiPen “Settlement” – What It Is and What It Isn’t

by Mintz Levin - Health Law & Policy Matters
Contact

Our eyebrows were raised by Mylan’s October 7, 2016 announcement that it had reached a $465 million “settlement” with the United States Department of Justice (DOJ) and “other government agencies” over its Medicaid Drug Rebate obligations for EpiPen.  The timing of the announcement was especially eyebrow-raising:  close to 5 pm on a Friday afternoon at the start of a long holiday weekend (Columbus Day), which effectively forestalled any government comment on the announcement.

Let’s recap how we got here. Over the last few months, multiple state and federal government entities, including Congress, had raised concerns about the EpiPen’s classification for the purpose of Medicaid Drug Rebates.  Manufacturers pay lower Medicaid rebate percentages on generic drugs than on brand name or innovator drugs.  Manufacturers also face a Medicaid Drug Rebate “inflation penalty” when price increases for brand name/innovator drugs outpace inflation; generic drugs are exempt from the inflation penalty.   But the “Epi” part of EpiPen was the generic drug epinephrine; it was the “Pen” part, the distribution unit, which was patented and unique.  More than 18 years ago, CMS said that it was reasonable to base EpiPen Medicaid Drug rebates on the “Epi” part, as a generic product.  Thus Mylan paid Medicaid drug rebates on EpiPen at the generic rate and faced no inflation penalty.   But earlier this year, after media reports focused on dramatic price increases for EpiPen and the lack of competitor products, questions have been raised as to whether Mylan knew, or should have known, that it needed to revisit the EpiPen classification and pay the higher higher brand/innovator Medicaid Drug Rebate rates, and face the inflation penalty, for EpiPen.

Mylan’s announcement states that the $465 million settlement provides “resolution of all potential rebate liability claims by federal and state governments as to whether the product should have been classified as an innovator drug for CMS purposes and subject to a higher rebate formula.”   But in the days following the Columbus Day holiday, details on the specifics of the settlement have not been forthcoming from Mylan or the government.

So as a result of the Mylan announcement, what do we know and what do we not know about the purported settlement?  Here are our top five takeaways from Mylan’s announcement.

1.     We think, but cannot be sure, that Mylan’s announcement likely represents the outline of a Civil False Claims Settlement based on Mylan’s alleged underpayment of EpiPen Medicaid Drug Rebate. Put another way, this is likely a handshake deal; we do know that actual settlement agreements have not been executed.

2.     According to Mylan, the terms of the settlement “do not provide for any finding of wrongdoing on the part of Mylan or any of its affiliated entities or personnel.” But many Civil False Claims settlements are accompanied by a criminal settlement, which would include findings and an admission of some wrongdoing.   We don’t know whether, in the absence of a full investigation, DOJ has really agreed to provide a criminal release for Mylan as part of this settlement. Moreover, we don’t know whether, in the absence of full investigation, DOJ has really agreed that as part of the corporate settlement, it will dodge the requirements of the Yates memo, and also provide a criminal and civil release for all Mylan personnel, including executives and managers.

3.     A corollary takeaway involves HHS-OIG. The Mylan announcement indicates the company “expects to enter” a Corporate Integrity Agreement with HHS-OIG, meaning one has yet to be negotiated. But that is not the only HHS-OIG role in any settlement of this matter. We know that HHS-OIG specifically reserves its right to consider corporate and individual officer/manager exclusion for corporate False Claims settlements, and recently updated some of its governing policies on such exclusions. We also know that DOJ cannot settle or waive exclusion issues for HHS-OIG. We don’t know what, if any, position HHS-OIG has taken on the settlement.

4.     The deal reached on Medicaid Drug Rebates is with US DOJ and “other government agencies” to resolve all potential rebate liability claims by federal and state governments. We do know that in fact, Medicaid Drug Rebates are paid to State Medicaid Agencies; while the amount of rebates the states get to retain will vary from state to state, on average it is close to 50% and closer to 55% if a settlement on Medicaid Drug Rebates is based on false claims liability. We also know that DOJ does not have the authority to settle states’ individual drug rebate claims against Mylan, which means any potential “global” settlement with the states raises a variety of issues, including:

  • We know that Medicaid Drug Rebate settlement terms for each individual state will have to be agreed to by each individual participating state’s Attorney General and in many states, also by the State Medicaid Agency.
  • In States that are heavily Medicaid managed care, we don’t know whether data was obtained to confirm the extent to which Medicaid Drug Rebates were paid for EpiPens covered through Medicaid managed care, as required by the ACA, and whether applicable state law/process even addresses the state’s authority to release managed care contractors’ claims regarding Medicaid drug rebates. Meaning as a practical matter, we don’t know whether theoretically Mylan could still be facing claims from individual Medicaid managed care plans.
  • We do know that many states negotiate supplemental Medicaid Drug Rebate agreements with drug manufacturers. We don’t know whether the data used to reach the $465 million settlement figure did in fact include alleged underpayment of any supplemental Medicaid Drug Rebates.
  • We know that certain state Attorneys General historically opt out of so-called “global” settlements involving Medicaid drug price reporting or rebates with pharmaceutical manufacturers. Instead, these states deputize private attorneys to act as “special” assistant Attorneys General to pursue individual state cases on behalf of the Attorney General’s office, often on a contingency fee basis. According to the New York Times, while the practice is controversial it is also lucrative for those involved. Given the money at issue, in all likelihood multiple Attorneys General are already being lobbied to forgo the federal settlement to instead pursue an individual state action against Mylan with the counsel of their choice. We don’t know the number of individual states that have actually committed to the “global” settlement outline; we do know that there is nothing DOJ or Mylan can do to prevent a state opting out of the federal settlement to pursue its own Medicaid Drug Rebate case against Mylan.

5.     We know that the announced settlement will only address issues involving Medicaid Drug Rebates; it will not address or release any non-Medicaid based violation of law. So even if the announced settlement is finalized, we know that the settlement will not resolve a myriad of government investigations that still may be pursued against Mylan, including:

  • Congressional investigations led by Senate Judiciary Committee Chairman Grassley, Senate Finance Committee Ranking Member Wyden, and the bipartisan House Oversight and Government Reform Committee. We know that Congressional scrutiny will not be limited to Mylan’s conduct, but include how CMS classified EpiPen, and other similar products, for Medicaid Drug Rebate and how DOJ approached the Mylan settlement. We also know that Congress will be extremely skeptical of any hint that that DOJ let Mylan get off lightly.
  • State or Federal allegations of anti-competitive activity. Aside from any pay-to-delay concerns, we know that multiple states, including NY and WV, have confirmed investigations into whether Mylan’s contracts with school districts, which limited schools’ ability to use competitors’ products, violated the respective state antitrust laws. And we know that Senators Blumenthal and Klobuchar have asked the FTC to institute a similar, federal investigation.
  • State Consumer Protection Violations. We know that at least two state Attorneys General, in Minnesota and West Virginia, are actively investigating whether Mylan’s price increases for EpiPen violated respective state consumer protection laws. We also know that several class actions alleging violations of state consumer protection laws are also purportedly in the works, including one based on pricing and one based on the packaging of EpiPen.

So one week out, we know that Mylan’s announcement of a settlement does not mean the company has succeeded in evading government inquiries into its pricing and marketing of EpiPen. And we know that even if the settlement with DOJ is finalized on the terms outlined by Mylan, the settlement will not allow Mylan to avoid producing discovery on its marketing, sales and pricing practices for EpiPen, be it to DOJ, HHS-OIG, the FTC, a state attorney general, or Congress.  And we know that along with many of you, we will continue to follow this saga with interest.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz Levin - Health Law & Policy Matters | Attorney Advertising

Written by:

Mintz Levin - Health Law & Policy Matters
Contact
more
less

Mintz Levin - Health Law & Policy Matters on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.